Paclitaxel sensitizes homologous recombination-proficient ovarian cancer cells to PARP inhibitor via the CDK1/BRCA1 pathway
Nozomu Yanaihara(Jikei University School of Medicine), Aikou Okamoto(Jikei University School of Medicine)
Cited by 15
Related Papers
MicroRNA Expression Profiles Associated With Prognosis and Therapeutic Outcome in Colon Adenocarcinoma
|JAMA|2008|1.6k
Intraperitoneal Carboplatin for Ovarian Cancer — A Phase 2/3 Trial
|NEJM Evidence|2023|31
Bevacizumab increases the sensitivity of olaparib to homologous recombination-proficient ovarian cancer by suppressing CRY1 via PI3K/AKT pathway
|Frontiers in Oncology|2024|13